Compare Travere Therapeutics Inc. Common Stock (TVTX) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs US Bancorp — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while US Bancorp trades at $56.26 (market cap $88.64B). The key difference: US Bancorp is far larger — about 18.2× Travere Therapeutics Inc. Common Stock's market cap, and US Bancorp pays a 3.8% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and US Bancorp for 98 Days on average.
| TVTX | USB | |
|---|---|---|
Market Cap | $4.88B | $88.64B |
Volume | 1,668,577 | 8,200,583 |
Sector | Health | Financials |
52-Week High | $67.52 | $65.42 |
52-Week Low | $26.79 | $45.47 |
Typical Hold Time | 0 Days | 98 Days |
Enterprise Value | $5.01B | $118.14B |
Dividend Yield | — | 3.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
U.S. Bancorp (USB) trades at $56.89, down 0.92% with bearish technical signals but strong fundamentals including consistent earnings beats and a 27.61% net margin. The stock shows a P/E of 11.36 and ROE of 13.53%, with analyst consensus at Buy (51%) and a $69.94 price target. Recent news highlights dividend increases and strong Q3 expectations for net interest income and fee revenues.
Outlook remains positive based on valuation and earnings momentum, though risks include regulatory changes and interest rate sensitivity. The 3.8% dividend hike to $0.54 signals management confidence, but investors should monitor net cash flow trends and competitive pressures in regional banking.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
